Maturity onset diabetes of the young (MODY) is a clinically and genetically heterogeneous subgroup of non-autoimmune diabetes, constituting 1-2% of all diabetes. Because little is known about incretin function in patients with MODY, we studied the incretin effect and hormone responses to oral and intravenous glucose loads in patients with glucokinase (GCK)-diabetes (MODY2) and hepatocyte nuclear factor 1α (HNF1A)-diabetes (MODY3), respectively, and in matched healthy control individuals (CTRLs). Both MODY groups exhibited glucose intolerance after oral glucose (most pronounced in patients with HNF1A-diabetes), but only patients with HNF1A-diabetes had impaired incretin effect and inappropriate glucagon responses to OGTT. Both groups of patients with diabetes showed normal suppression of glucagon in response to intravenous glucose. Thus, HNF1A-diabetes, similar to type 2 diabetes, is characterized by an impaired incretin effect and inappropriate glucagon responses, whereas incretin effect and glucagon response to oral glucose remain unaffected in GCK-diabetes, reflecting important pathogenetic differences between the two MODY forms.
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INTRODUCTION
Maturity onset diabetes of the young (MODY) represents monogenic forms of nonautoimmune diabetes characterized by autosomal dominant inheritance, non-insulin dependent diabetes at onset, and diagnosis often before 25 years of age (1) . MODY is a clinically and genetically heterogeneous form of diabetes, with mutations in at least eight different genes, leading to specific forms of MODY (2, 3) . The two most common forms result from mutations in the genes encoding glucokinase (GCK) (GCK-diabetes: MODY2; 10 to 20% of all MODY patients (4, 5) ) and hepatocyte nuclear factor 1α (HNF1A) (HNF1A-diabetes: MODY3; 36 to 60% of all MODY patients (4, 5) ). More than 50% of carriers of HNF1A mutations develop diabetes before the age of 25 years with a lifetime risk above 95%.
Typically the disease shows a rapid progression from impaired glucose tolerance to overt diabetes due to continued deterioration of beta cell function (6) . Less than half of the carriers of GCK mutations are diagnosed with diabetes. The mutation results in a 'glucose sensing' defect with an increased plasma glucose (PG) threshold (by 1 to 2 mmol/L) for secretion of insulin, resulting in higher PG levels in GCK-diabetes patients as compared to healthy individuals(7).
The incretin effect describes the amplification of insulin response after oral glucose compared to glucose administered intravenously (8) and is a major contributor to normal glucose tolerance. Normal regulation of glucagon secretion is also essential, but little is known about incretin and glucagon physiology in patients with MODY. Here, we report incretin effect, and glucagon and incretin hormone responses in patients with HNF1A-diabetes and GCKdiabetes, respectively, and in a group of healthy control individuals (CTRLs). The experimental days were compared using paired two-sample t test (two-tailed). Insulin secretion rate (ISR) values were calculated by deconvolution of measured C-peptide concentrations and application of population-based variables for C-peptide kinetics.
Insulinogenic index was used to assess beta cell secretory function, and was calculated based 
RESULTS

Glucose.
Time courses for PG are illustrated in Fig. 1 ; baseline, peak and AUC values are given in Table 1 . Fasting PG (FPG) was higher in patients with GCK-diabetes and HNF1A-diabetes compared to CTRLs. AUC for PG during OGTT was higher in both patients with GCK-diabetes and HNF1A-diabetes compared to CTRLs. Isoglycemia was obtained in all groups (P = 0.991 (CTRL); P = 0.931 (GCK-diabetes); P = 0.885 (HNF1A-diabetes) (Fig. 1 ).
The amount of glucose needed to obtain isoglycemia during IIGI was higher in patients with Patients with HNF1A-diabetes had lower peak ISR compared to GCK-diabetes and CTRLs, and exhibited lower ISR responses during OGTT compared to CTRLs and GCK-diabetes patients, while the difference was only significant between patients with HNF1A-diabetes and GCK-diabetes during IIGI. In all groups ISR responses were higher during OGTT compared to IIGI. The incretin effect, calculated from insulin release, was similar in CTRLs and patients with GCK-diabetes (CTRL: 48 ± 5%; GCK-diabetes: 44 ± 3%; P = 0.587), whereas patients with HNF1A-diabetes exhibited a lower incretin effect (HNF1A-diabetes: 19 ± 8%) compared to the other groups (vs. CTRL: P = 0.008; vs. GCK-diabetes: P = 0.011). When calculating the incretin effect from C-peptide and ISR patients with HNF1A-diabetes exhibited lower incretin effect (C-peptide: HNF1A-diabetes: 17 ± 5%; GCK-diabetes: 26 ± 3%; CTRL: 37 ± 4%) compared to CTRLs (C-peptide: P = 0.018; ISR: P = 0.031) but not to patients with GCK-diabetes (C-peptide: P = 0.216; ISR: P = 0.602). The differences between patients with GCK-diabetes and CTRLs were not significant (C-peptide: P = 0.145; ISR: P = 0.499).
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For Peer Review Only Diabetes Additionally, patients with HNF1A-diabetes had lower beta cell secretory capacity according to insulinogenic index than CTRLs and patients with GCK-diabetes (Table 1) .
Insulin sensitivity. According to HOMA IR and Matsuda index (Table 1) patients with GCKdiabetes tended to be more insulin resistant than CTRLs and patients with HNF1A-diabetes.
Glucagon. Similar fasting values were observed on the two days in each group ( Table 2) . As illustrated in Fig. 2 , plasma glucagon dropped abruptly in the CTRLs and in the patients with GCK-diabetes following both oral and intravenous administration of glucose and continued to decrease for 60 minutes with equal suppression following OGTT and IIGI. In contrast, in patients with HNF1A-diabetes glucagon secretion initially increased following OGTT and later decreased to values that were lower than those observed after IIGI, which resulted in immediate suppression of glucagon levels ( Fig. 2 and Table 2 ).
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).
Plasma GIP and GLP-1 levels increased during the OGTT, but remained unchanged after the IIGI. Responses were similar in the three groups ( Fig. 2 and Table 2 ).
Gastric emptying (acetaminophen).
Similar gastric emptying, assessed by the acetaminophen absorption test, was seen in all groups (Table 2) .
DISCUSSION
The primary findings in our study are 1) a normal incretin effect and glucagon response in patients with GCK-diabetes, 2) a reduced incretin effect and inappropriate suppression of glucagon during OGTT (but not during IIGI) in patients with HNF1A-diabetes, and 3) normal responses of the gut incretin hormones GIP and GLP-1 to oral glucose in patients with GCKdiabetes and HNF1A-diabetes.
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The effects of GCK and HNF1A mutations for the incretin effect and glucagon responses to glucose were unclear until now. It has been shown that mutations in GCK, the ratedetermining enzyme converting glucose to glucose-6-phosphate in the beta cells, may result in an increased glucose threshold for insulin secretion(3,5,7). Our findings demonstrate that patients with GCK-diabetes have intact insulin responses to both oral and intravenous glucose administration, supporting the view that patients with GCK-diabetes primarily have a 'glucose-sensing defect' in their beta cells. In spite of their impaired glucose tolerance, they also had a normal incretin effect consistent with the interpretation that they do not have 'true' diabetes, but 'benign familial hyperglycemia', not requiring blood glucose-lowering drugs(3).
We also found completely normal suppression of glucagon in response to both intravenous and oral glucose stimulation in patients with GCK-diabetes, supporting this concept. It has previously been shown that insulin resistance may develop in patients with GCKdiabetes(10). However, the slightly elevated HOMA IR and lowered Matsuda index in our patients may merely reflect a higher 'set point' for glucose uptake in the hepatocytes, which also depend on glucokinase for normal glucose phosphorylation.
In contrast, mutations in HNF1A result in progressive beta cell dysfunction, involving impaired expression of the genes encoding insulin and the glucose transporter 2 (GLUT2) as well as reduced pyruvate kinase activity resulting in reduced formation of ATP (3, (11) (12) (13) , eventually leading to decreased insulin secretion and thereby glucose intolerance. Since the incretin hormones act to enhance glucose-induced insulin secretion, a diminished incretin effect might be expected in patients with HNF1A-diabetes, consistent with the findings in our study. Insulin sensitivity was normal in our patients with HNF1A-diabetes as also found previously (10, 14) , but in contrast to a tendency of reduced insulin sensitivity found in another study (15) . Thus, insulin resistance does not seem to be involved in their reduced incretin
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For Peer Review Only Diabetes effect, and neither does changes in the release of incretin hormones, which was normal both in this and two previous studies (OGTT (16) , and mixed meal(17)). We previously found an impaired insulinotropic action of particularly GIP in patients with HNF1A-diabetes during hyperglycemic (15 mmol/L) clamps (18) suggesting that a reduced sensitivity to the incretin hormones may explain the impaired incretin effect. A reduced action of the incretin hormones in HNF1A-diabetes may be due to the reduced formation of ATP since the incretin hormones may act to sensitize the K ATP -channels to ATP via formation of cAMP and activation of protein kinase A (19) (20) (21) . In addition to impaired beta cell function, it is possible that defective HNF1A may influence other cell types, i.e. alpha cells and hepatocytes, although this remains to be elucidated. Also defective GIP and/or GLP-1 receptor signaling caused by the HNF1A mutation could be involved.
Normal glucose tolerance depends on normal regulation of glucagon secretion. In a previous study patients with HNF1A-diabetes suppressed glucagon normally during a hyperglycemic clamp(18) similar to our finding of normal glucagon suppression following intravenous glucose administration, but we also found delayed suppression following OGTT similar to patients with type 2 diabetes (22) . The role of HNF1A in the alpha cell is not known. The normal suppression during IIGI seems to exclude that a defective beta cell function is responsible.
Treatment of patients with MODY using an incretin-based strategy has been described in a few cases (23, 24) . Our study demonstrates that HNF1A-diabetes shares incretin-related pathophysiology with type 2 diabetes; i.e. reduced incretin effect, which was one of the incentives for incretin-based treatment for type 2 diabetes. Therefore, incretin-based therapy to patients with HNF1A-diabetes seems relevant and randomized, controlled clinical trials might be considered.
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In conclusion, patients with GCK-diabetes exhibit preserved incretin physiology while patients with HNF1A-diabetes are characterized by a reduced incretin effect, a marked beta cell dysfunction and an inappropriate glucagon response to OGTT, but have normal insulin sensitivity. 2139 ± 59* (1, 3) 3042 ± 302* (1, 2) <0.001 IIGI 1376 ± 26* (2, 3) 2204 ± 65* (1, 3) 3154 ± 311* (1, 2) <0.001
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